Market Updates

Lallemand Acquires BIO-CAT

The acquisition will significantly boost Lallemand's capabilities in enzymes and microbials.

Photo: Mongkolchon | Adobe Stock

Lallemand, a global, vertically integrated probiotic manufacturer and specialist in fermentation-derived ingredients, has completed its acquisition of BIO-CAT, a biotechnology company specializing in enzymes and microbial technologies for human health, agriculture, and animal nutrition.

The two family-owned companies will combine their complementary strengths in enzymes, microbial technologies, fermentation, and life science to develop new solutions in human health, animal nutrition, agriculture, food, and other industrial markets.

“When my father Ed Schuler and I founded BIO-CAT in 1988, we built the company around family values, science, integrity, and lasting relationships,” said Chris Schuler, CEO and co-founder of BIO-CAT. “Finding a partner with shared values was just as important as finding one with complementary technologies. Lallemand’s family-owned heritage, long-term vision, and commitment to its people and customers made this a natural fit, and we’re excited about what we’ll accomplish together.”

“The acquisition will reinforce our presence in the dietary food supplement and health ingredient markets, and increase our production footprint and capacity in the U.S. This, in turn, should better enable us to meet the requirements of our existing and new customers across the global animal nutrition, agriculture, and food industries.”

The financial terms of the transaction were not disclosed.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters